Health

Third Rock Ventures has led a series A round for Abata Therapeutics that also featured fellow existing investor ElevateBio.

Third Rock Ventures has led a series A round for Abata Therapeutics, launched by the firm to commercialise research from Harvard, MIT, Johns Hopkins, NIH and UZH.

The eyewear retailer’s Lenskart Vision Fund will invest in eyecare and retail technology developers on behalf of its corporate parent.

Gilead Sciences, Yipinhong Pharmaceutical and Mass General Brigham Ventures helped the slow-release drug developer secure series C cash bringing its overall funding to almost $250m.

GV participated in a series C round for the fertility and gynaecology services provider at a $612m valuation, doubling its overall funding.

A number of corporate backers scored an exit from trucking services marketplace Full Truck Alliance (Manbang Group), as the latter went public in the US. This transaction exemplifies an upward trend in exits for corporate-backed businesses from the transport and mobility space.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Waste management software provider Recycle Track Systems bagged $35m in a Citi-led series C round while muscular dystrophy drug developer Vita Therapeutics completed a $32m series A.

The AstraZeneca, Sinopharm and Eli Lilly-backed oncology drug developer has revealed its intention to go public in a Hong Kong IPO that could reportedly fetch $250m.

Gene therapy developer Corlieve, which utilises University of Bordeaux, Aix Marseille University, CNRS and Inserm research, is set to be acquired by peer QniQure for about $55m.

GV notched up an exit as cancer therapy developer Monte Rosa Therapeutics priced an upsized initial public offering at the top of its range.